Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents.

BACKGROUND Combination antifungal/corticosteroid preparations are widely used by nondermatologists in the treatment of superficial fungal infections in patients of all ages. Over half of the prescriptions written for the most commonly used combination agent clotrimazole 1%/betamethasone diproprionate 0.05% cream (Lotrisone, Schering, Kenilworth, NJ) were prescribed for children younger than 4 years old. Our pediatric dermatology division has recently encountered a series of children with recurrent or persistent tinea corporis, especially tinea faciei, treated initially with combination antifungal/corticosteroid cream. METHODS All children evaluated for tinea corporis in a university hospital pediatric dermatology clinic from January through June 2001 were identified from the clinic registry for a retrospective chart review. Response to therapy was confirmed by telephone survey and/or follow-up visits at least 1 month after clearing of infection. RESULTS Six children ranging in age from 4 to 11 years were evaluated for tinea corporis in a pediatric dermatology clinic at our institution during the 6-month period. All 6 children were diagnosed clinically by their pediatrician with tinea corporis and initially treated with clotrimazole 1%/betamethasone diproprionate 0.05% cream for 2 to 12 months. In our pediatric dermatology clinic, patients had their diagnosis confirmed with a positive potassium hydroxide preparation and were treated with one of several oral or topical antifungal agents with clearing of all tinea infections. CONCLUSION The use of combination clotrimazole 1% cream/betamethasone diproprionate 0.05% cream (Lotrisone) for the treatment of tinea corporis may be associated with persistent/recurrent infection.

[1]  A. Fleischer,et al.  Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians. , 1999, Clinical therapeutics.

[2]  A. Fleischer,et al.  Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994. , 1998, Journal of the American Academy of Dermatology.

[3]  B. Elewski,et al.  Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis. , 1996, Cutis.

[4]  B. Elewski,et al.  Guidelines of care for superficial mycotic infectionsof the skin: Tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis , 1996 .

[5]  T. Rosen,et al.  Failure of clotrimazole-betamethasone dipropionate cream in treatment of Microsporum canis infections. , 1995, Journal of the American Academy of Dermatology.

[6]  Mostafa Mokhtar,et al.  NAFTIEINE VERSUS MICONAZOLE/HYDROCORTISONE IN INFLAMMATORY DERMATOPHYTE INFECTIONS , 1994, International journal of dermatology.

[7]  L. Millikan,et al.  Double-blind comparison of naftifine cream and clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis. , 1992, Journal of the American Academy of Dermatology.

[8]  A. Lucky,et al.  Exacerbation of tinea corporis during treatment with 1% clotrimazole/0.05% betamethasone diproprionate (Lotrisone) , 1991, American journal of diseases of children.

[9]  W. F. Barkey Striae and persistent tinea corporis related to prolonged use of betamethasone dipropionate 0.05% cream/clotrimazole 1% cream (Lotrisone cream) , 1987, Journal of the American Academy of Dermatology.

[10]  G. Cole,et al.  SCH 370 (clotrimazole-betamethasone dipropionate) cream in patients with tinea cruris or tinea corporis. , 1984, Cutis.

[11]  Wortzel Mh A double-blind study comparing the superiority of a combination antifungal (clotrimazole)/steroidal (betamethasone dipropionate) product. , 1982 .